{{medical}}
[[Image:Incretins_and_DPP_4_inhibitors.svg|thumb]]
'''二肽基肽酶-4抑制剂（{{lang-en|Dipeptidyl peptidase-4 inhibitor}}）'''，或称'''DPP-4 抑制剂'''或'''列汀类药物'''，是一种通过抑制[[二肽基肽酶-4|二肽基肽酶-4]]来发挥作用的口服[[抗糖尿病药|抗糖尿病药]] ，用来治疗[[2型糖尿病|2型糖尿病]]。

第一种二肽基肽酶-4抑制剂是[[西格列汀|西格列汀]]，于2006年通过了[[美国食品药品监督管理局|美国食品药品监督管理局]]（USFDA）的审批。<ref name=FDAapproval>{{cite press release
  | title = FDA Approves New Treatment for Diabetes
  | publisher = U.S. Food and Drug Administration
  | date = October 17, 2006
  | url = http://www.fda.gov/bbs/topics/NEWS/2006/NEW01492.html
  | accessdate = 2006-10-17
  | archive-date = 2009-05-13
  | archive-url = https://web.archive.org/web/20090513071617/http://www.fda.gov/bbs/topics/NEWS/2006/NEW01492.html
  | dead-url = no
  }}</ref>

[[胰高血糖素|胰高血糖素]]提高[[血糖|血糖]]水平，DPP-4抑制剂可以减少胰高血糖素和降低血糖水平。DPP-4抑制剂的原理为增加可以抑制胰高血糖素释放的[[肠促胰岛素激素|肠促胰岛素激素]]的水平（[[GLP-1|GLP-1]]（胰高血糖素样多肽-1）和[[GIP|GIP]]（葡萄糖依赖性促胰岛素多肽）），增加[[胰岛素|胰岛素]]分泌，减慢胃排空，降低血糖水平。<ref name="pmid15780435">{{cite journal |pages=159–65 |doi=10.1016/j.regpep.2004.06.001 |title=Dipeptidyl peptidase IV inhibitors: How do they work as new antidiabetic agents? |year=2005 |last1=McIntosh |first1=C |last2=Demuth |first2=H |last3=Pospisilik |first3=J |last4=Pederson |first4=R |journal=Regulatory Peptides |volume=128 |issue=2 |pmid=15780435}}</ref><ref name="pmid12697069">{{cite journal |pmc=154101 |doi=10.1186/1472-6823-3-3 |year=2003 |last1=Behme |first1=Margaret T |last2=Dupré |first2=John |last3=McDonald |first3=Thomas J |journal=BMC Endocrine Disorders |volume=3 |page=3 |pmid=12697069 |title=Glucagon-like peptide 1 improved glycemic control in type 1 diabetes |issue=1}}</ref><ref name="pmid7789625">{{cite journal |pages=626–30 |doi=10.2337/diabetes.44.6.626 |title=Glucagon-like peptide I reduces postprandial glycemic excursions in IDDM |url=https://archive.org/details/sim_diabetes_1995-06_44_6/page/626 |year=1995 |last1=Dupre |first1=J. |last2=Behme |first2=M. T. |last3=Hramiak |first3=I. M. |last4=McFarlane |first4=P. |last5=Williamson |first5=M. P. |last6=Zabel |first6=P. |last7=McDonald |first7=T. J. |journal=Diabetes |volume=44 |issue=6 |pmid=7789625}}</ref>

近期的[[芸萃分析|芸萃分析]]（meta）发现，DPP-4抑制剂不会影响[[全因死亡率|全因死亡率]]、[[心血管疾病|心血管疾病]]死亡率及[[中风|中风]]的风险，但是发生[[心力衰竭|心力衰竭]]的几率有轻微的统计学上的上升。<ref>{{cite journal |author=Wu S, Hopper I, Skiba M, Krum H |title=Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: Meta-analysis of randomized clinical trials with 55,141 participants |journal=Cardiovasc Ther |volume= |issue= |pages= |date=April 2014  |pmid=24750644 |doi=10.1111/1755-5922.12075 |url=}}</ref>

==药物列表==
* [[西格列汀|西格列汀]]<ref>{{UTGlucagon|sitagliptin}}</ref> (2006年通过FDA审批，商品名为捷诺维，由[[默克制药|默克制药]]研发和销售。),
* [[维格列汀|维格列汀]]<ref>{{UTGlucagon|vildagliptin}}</ref> (2007年通过[[欧盟|欧盟]]审批，商品名为佳维乐，由[[诺华制药|诺华制药]]研发和销售。),
* [[沙格列汀|沙格列汀]] (2009年通过FDA审批，商品名为安立泽，由[[百时美施贵宝|百时美施贵宝]]制药研发和销售)
* [[利格列汀|利格列汀]] (2011年通过FDA审批，商品名为欧唐宁，由[[礼来|礼来]]和[[勃林格殷格翰|勃林格殷格翰]]研发和销售。<ref>{{cite web |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm |title=FDA approves new treatment for Type 2 diabetes |publisher=Fda.gov |date=2011-05-02 |accessdate=2013-04-15 |archive-date=2013-11-03 |archive-url=https://web.archive.org/web/20131103093137/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm253501.htm |dead-url=no }}</ref>
* [[安奈格列汀|安奈格列汀]] (2012年在[[日本|日本]]通过审批，由三和化学研究所有限公司和科瓦股份有限公司研发。)<ref>{{cite web |url=http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2012.pdf |title=存档副本 |accessdate=2013-08-07 |deadurl=yes |archiveurl=https://web.archive.org/web/20130718002132/http://www.pmda.go.jp/english/service/pdf/list/NewdrugsFY2012.pdf |archivedate=2013-07-18 }}</ref>
* [[替格列汀|替格列汀]](2012年在日本通过审批)<ref>{{cite journal | journal = Annual Reports in Medicinal Chemistry | volume = 48 | pages = 523–524 | title = Teneligliptin (Antidiabetic) | chapter = To Market, To Market - 2012 | author = Joanne Bronson, Amelia Black, T. G. Murali Dhar, Bruce A. Ellsworth, and J. Robert Merritt | doi=10.1016/b978-0-12-417150-3.00028-4}}</ref>
* [[阿格列汀|阿格列汀]] (2013年通过FDA审批， 商品名为尼欣那，由日本[[武田制药|武田制药]]研发。)
* [[曲格列汀|曲格列汀]] (2015年在日本通过审批)
* [[吉米格列汀|吉米格列汀]] (正由韩国[[LG|LG]]研发)<ref>{{cite web |url=http://www.lgls.com/rd/pipeline.jsp |title=LG Life Science |publisher=Lgls.com |accessdate=2013-04-15 |archive-date=2013-09-06 |archive-url=https://web.archive.org/web/20130906063308/http://www.lgls.com/rd/pipeline.jsp |dead-url=yes }}</ref>
* {{tsl|en|Dutogliptin|度格列净}} (正由Phenomix公司研发，已达[[临床试验|III期临床试验]]阶段)<ref>"Forest Splits With Phenomix", San Diego Business Journal, Tuesday, April 20, 2010 http://www.sdbj.com/news/2010/apr/20/forest-splits-phenomix/ {{Wayback|url=http://www.sdbj.com/news/2010/apr/20/forest-splits-phenomix/ |date=20201001233527 }}</ref>
* [[奥格列汀|奥格列汀]] (MK-3102)（正由[[默克制药|默克制药]]研发，近期的研究指出此药可以一周给药一次，并且耐受性很好。<ref name="omarigliptin_research">{{cite web | url=http://care.diabetesjournals.org/content/early/2015/08/26/dc15-0109 | title=Safety and Efficacy of Omarigliptin (MK-3102), a Novel Once-Weekly DPP-4 Inhibitor for the Treatment of Patients With Type 2 Diabetes | accessdate=18 September 2015 | archive-date=2015-09-17 | archive-url=https://web.archive.org/web/20150917014514/http://care.diabetesjournals.org/content/early/2015/08/26/dc15-0109 | dead-url=no }}</ref>但是由于安全性不及预期以及价格与销售上的原因已经停止研发。<ref>{{Cite web|url=https://www.yypharm.com/?p=6678|title=默沙东终止长效DPP4抑制剂omarigliptin研发|accessdate=2018-03-16|author=|date=|work=美中药源|publisher=|language=zh-hans|archive-date=2019-07-30|archive-url=https://web.archive.org/web/20190730010036/https://www.yypharm.com/?p=6678|dead-url=no}}</ref>）

其它也可抑制二肽基肽酶-4的成分：
* [[小檗碱|小檗碱]]，一种常见[[草药|草药]]的主要成分，也可以抑制二肽基肽酶-4，至少部分解释了它的降糖活性。<ref>{{cite journal |pages=1061–6 |doi=10.1080/14756360802610761 |title=Inhibition of dipeptidyl peptidase IV (DPP IV) is one of the mechanisms explaining the hypoglycemic effect of berberine |year=2009 |last1=Al-Masri |first1=Ihab M. |last2=Mohammad |first2=Mohammad K. |last3=Tahaa |first3=Mutasem O. |journal=[[Journal_of_Enzyme_Inhibition_and_Medicinal_Chemistry|Journal of Enzyme Inhibition and Medicinal Chemistry]] |volume=24 |issue=5 |pmid=19640223}}</ref>
* [[羽扇豆醇|羽扇豆醇]]，在[[芒果|芒果]]、[[红桤木|红桤木]]、[[蒲公英咖啡|蒲公英咖啡]]中都有发现。

==引用==
{{reflist}}

{{口服降糖药和胰岛素类似物}}
{{Diabetes}}

[[Category:糖尿病药物|Category:糖尿病药物]]